Overview

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Status:
Recruiting
Trial end date:
2023-02-18
Target enrollment:
Participant gender:
Summary
patients with MDS (Myelodysplastic Syndrome) and mutated IDH2 patients will be treated with AG221 (IDH2 inhibitor)
Phase:
Phase 2
Details
Lead Sponsor:
Groupe Francophone des Myelodysplasies